ADMA will submit BLA on Phase III RI-002 results
This article was originally published in Scrip
Executive Summary
Ramsey, New Jersey-based ADMA Biologics will submit a biologics license application (BLA) to the US FDA during the first half of 2015 based on positive Phase III clinical trial results for RI-002 in the prevention of serious bacterial infections in patients with primary immune deficiency disease (PIDD).